Non-Hormonal Therapies for Endometriosis: New Hope Beyond Hormones

Endometriosis affects 10–15% of reproductive-aged women, causing chronic pelvic pain, severe menstrual cramps (dysmenorrhea), and infertility. For many, first-line hormonal treatments—like birth control pills or hormonal IUDs—help manage symptoms but come with trade-offs: they can disrupt ovulation (critical for women trying to conceive) and often lead to pain recurrence once stopped.

But there’s growing hope for non-hormonal therapies—treatments that target endometriosis without altering hormone levels. A 2019 review by researchers at Peking Union Medical College Hospital (Fang-Ying Chen, Xi Wang, and colleagues) analyzed 24 studies (9 animal, 15 human) to evaluate these emerging options. Here’s what you need to know about the most promising candidates and their potential to change care.

Why Non-Hormonal? The Limitations of Hormonal Treatment

Hormonal therapies work by lowering estrogen (a hormone that fuels endometriosis lesions) or mimicking pregnancy to suppress the menstrual cycle. While effective for pain, they:

Interfere with fertility: Many block ovulation, making it hard for women to get pregnant during treatment.
Have high recurrence rates: Pain often returns within a year of stopping treatment.
Cause side effects: Mood changes, hot flashes, and bone density loss are common with long-term use.

Non-hormonal therapies target other drivers of endometriosis—like inflammation, blood vessel growth (angiogenesis), or abnormal cell proliferation—without touching hormones. This makes them ideal for women trying to conceive or those who can’t tolerate hormonal side effects.

1. NSAIDs: Targeting Inflammation and Pain

Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are commonly used for menstrual pain, but COX-2 inhibitors—a subset that specifically blocks an enzyme (cyclooxygenase-2) linked to endometriosis inflammation—are under study.

Parecoxib: Animal studies show it shrinks endometriosis lesions by reducing blood vessel growth (via VEGF, a protein that fuels new vessels). A mouse study found combining parecoxib with the blood pressure drug telmisartan worked even better, slowing cell growth and promoting lesion death. But no human trials exist yet.
Rofecoxib: A small pilot study of 28 women with mild endometriosis found rofecoxib relieved pain better than a placebo and prevented recurrence.rofecoxib was withdrawn from the market in 2004 due to severe cardiovascular risks (heart attacks, strokes) with long-term use.

Takeaway: COX-2 inhibitors show anti-inflammatory and anti-angiogenic effects in animals, but safety concerns limit human use.

2. TNF-Alpha Antagonists: Fighting Inflammation and Infertility

Tumor necrosis factor-alpha (TNF-α) is an inflammatory protein found at higher levels in the pelvic fluid of women with endometriosis. It’s linked to both pain and infertility—making TNF-α blockers a dual-target therapy.

Etanercept: A rat study found etanercept (a TNF-α receptor blocker) shrank lesions by 32%. A small human study of 68 infertile women with endometriomas found those who took etanercept before IVF had a 4x higher pregnancy rate (though live birth rates weren’t statistically different). More research is needed to confirm these results.
Pentoxifylline: This old drug—used for decades to improve blood flow in peripheral vascular disease—has anti-inflammatory effects that help endometriosis. Four human trials (including randomized controlled trials, or RCTs) suggest pentoxifylline:
- Relieves pelvic pain, dysmenorrhea, and dyspareunia (painful sex).
- Doesn’t harm fertility (critical for women trying to conceive).
- Has no serious side effects in short-term use (though gastrointestinal issues are common in other uses).

Takeaway: Pentoxifylline is one of the most promising non-hormonal options, with more human data than most others.

3. Natural Agents: Resveratrol and Green Tea

Natural compounds are gaining attention for their anti-inflammatory and anti-proliferative effects. Two stand out:

Resveratrol: Found in red grapes, blueberries, and peanuts, resveratrol blocks enzymes (like aromatase and COX-2) that fuel endometriosis. A pilot study of 42 women found combining resveratrol with birth control pills relieved pain better than pills alone and stopped breakthrough bleeding. But a larger RCT of 44 women found no extra benefit when adding resveratrol to birth control—likely due to a short treatment period (42 days) and small sample size. Side effects like headaches and nausea were rare but reported.
EGCG: Epigallocatechin-3-gallate (EGCG), the main active compound in green tea, stops VEGF production—cutting off blood supply to lesions. Animal studies show EGCG shrinks lesions without harming ovarian follicles (critical for fertility). A phase II RCT of green tea extract is underway, but human data are limited. A prodrug (EGCG octaacetate) that boosts absorption is being tested in mice and could overcome EGCG’s poor bioavailability (low absorption in humans).

Takeaway: Resveratrol has mixed human results, but EGCG’s safety and anti-angiogenic effects make it a top candidate for future trials.

4. Anti-Angiogenesis: Cutting Off Lesion Blood Supply

Endometriosis lesions need new blood vessels to grow—so therapies that block angiogenesis (blood vessel formation) are a logical target.

Endostatin: A protein that stops VEGF, endostatin shrank human endometriosis lesions in mouse studies by reducing microvessel density. A Korean study found lower endostatin levels in women with early-stage endometriosis, suggesting it may protect against lesion growth. No human trials exist yet.
Rapamycin/Everolimus: Rapamycin (used in organ transplants to prevent rejection) targets a pathway (mTOR) that controls cell growth. Animal studies show it shrinks lesions by blocking VEGF and cell proliferation. Everolimus—an oral version—was tested in 35 women with recurrent endometriosis: 21% had a clinical benefit (lesion shrinkage or pain relief), and all had stable disease after 20 weeks. Side effects like fatigue and nausea were common but manageable.

Takeaway: Anti-angiogenic therapies are early-stage but show promise for recurrent or severe endometriosis.

5. VEGF Inhibitors: Blocking Lesion Growth

VEGF is essential for endometriosis lesions to grow, so drugs that block VEGF or its receptors are being explored.

Cabergoline: A dopamine agonist used to treat pituitary tumors, cabergoline blocks VEGF binding to its receptor. A randomized study of 140 women found cabergoline shrank endometriomas (ovarian lesions) more effectively than a hormonal therapy (LHRH agonist). But cabergoline has serious side effects—like heart valve damage and gastrointestinal distress—that limit its use.
Quinagolide: A non-ergot dopamine agonist (no heart valve risks) that works like cabergoline but with fewer side effects. Animal studies show it shrinks lesions as well as cabergoline and doesn’t interfere with pregnancy. A phase II trial of 72 women with endometriomas is underway, but results aren’t published yet.

Takeaway: Quinagolide could be a safer alternative to cabergoline if human trials confirm its efficacy.

6. Statins: Lowering Cholesterol and Inflammation

Statins—best known for lowering cholesterol—also reduce inflammation and block angiogenesis. Two are under study:

Atorvastatin: Animal studies show high-dose atorvastatin shrinks lesions by 68%. An ongoing RCT (started in 2008) is comparing atorvastatin alone, birth control pills alone, or a combination for pain relief. Results are pending.
Simvastatin: A mouse study found simvastatin prevents endometriosis by reducing MCP-1 (a protein that drives inflammation and cell adhesion). Human data are limited: a small study of 60 women found simvastatin relieved pain as well as hormonal therapies, but no one had a second-look laparoscopy to confirm lesion shrinkage. A recent trial of 40 women found simvastatin didn’t reduce inflammation markers, suggesting a higher dose may be needed—but that increases the risk of muscle damage (myopathy).

Takeaway: Statins have anti-inflammatory and anti-angiogenic effects, but human data are too limited to recommend them yet.

The Most Promising Options (So Far)

Based on the review, pentoxifylline is the clear leader:

Four human trials (including RCTs) show it relieves pain without harming fertility.
No serious side effects reported in endometriosis studies.
It’s already approved for other conditions, so repurposing it for endometriosis could be faster.

EGCG (green tea) and quinagolide are also promising but need more human data.

What’s Next? The Need for Larger Trials

Most non-hormonal therapies are in early stages—limited to small pilot studies or animal models. To move them from the lab to the clinic, we need:

Large, randomized controlled trials (RCTs): The gold standard for testing efficacy and safety.
Standardized outcomes: Consistent measures of pain, lesion size, and fertility to compare studies.
Long-term follow-up: To assess recurrence rates and long-term safety (e.g., statin muscle damage, cabergoline heart risks).

Conclusion

Endometriosis is a chronic disease that needs lifelong management—but hormonal therapies aren’t the only option. Non-hormonal treatments like pentoxifylline, EGCG, and quinagolide target inflammation, angiogenesis, and cell growth without interfering with hormones or fertility. While most are in early stages, these therapies offer hope for women who can’t tolerate hormones or want to conceive.

The review by Chen et al. highlights the need for more research—but also shows that non-hormonal options are no longer a “nice-to-have” but a critical unmet need for endometriosis patients. As more trials are completed, we may soon have safer, more effective treatments that work with the body—not against it.

Original study citation: Chen FY, Wang X, Tang RY, et al. New therapeutic approaches for endometriosis besides hormonal therapy. Chinese Medical Journal. 2019;132(24):2984–2993. doi:10.1097/CM9.0000000000000569
For more on endometriosis guidelines, visit the American Society for Reproductive Medicine (ASRM).

Was this helpful?

0 / 0